138 related articles for article (PubMed ID: 15154823)
21. Potential Procedural Efficiencies and Challenges of Combining Multiple Type II Variations into a Single EU-RMP.
Marshall R; Atuah KN; Tekumalla SH
Pharmaceut Med; 2020 Feb; 34(1):1-5. PubMed ID: 32048215
[TBL] [Abstract][Full Text] [Related]
22. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
Vora P; Artime E; Soriano-Gabarró M; Qizilbash N; Singh V; Asiimwe A
Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):695-706. PubMed ID: 29663572
[TBL] [Abstract][Full Text] [Related]
23. Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use.
Santoro A; Caplanusi I; Sweeney F; Cappelli B; Nolan L; Straus S; Arlett P
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1343-1352. PubMed ID: 32954565
[TBL] [Abstract][Full Text] [Related]
24. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.
Rubino A; Artime E
Expert Opin Drug Saf; 2017 Aug; 16(8):877-884. PubMed ID: 28548608
[TBL] [Abstract][Full Text] [Related]
25. Pharmacovigilance and communicating safety information.
Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
[TBL] [Abstract][Full Text] [Related]
26. The Erice Manifesto: for global reform of the safety of medicines in patient care.
Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
[TBL] [Abstract][Full Text] [Related]
27. Obstacles to transparency over pharmacovigilance data within the EMA.
Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
[TBL] [Abstract][Full Text] [Related]
28. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
29. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
30. [Is it possible (and desirable) to administer a standard for an effective health policy for the European Union?].
Bruch M
Bull Soc Sci Med Grand Duche Luxemb; 1997; 134(2):5-10. PubMed ID: 9534267
[TBL] [Abstract][Full Text] [Related]
31. The IMI PROTECT project: purpose, organizational structure, and procedures.
Reynolds RF; Kurz X; de Groot MC; Schlienger RG; Grimaldi-Bensouda L; Tcherny-Lessenot S; Klungel OH
Pharmacoepidemiol Drug Saf; 2016 Mar; 25 Suppl 1():5-10. PubMed ID: 27038353
[TBL] [Abstract][Full Text] [Related]
32. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
Smith MY; Benattia I
Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
[TBL] [Abstract][Full Text] [Related]
33. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
Faden LB; Milne CP
Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
[No Abstract] [Full Text] [Related]
34. Drug safety in the European community.
Sauer F
Drug Saf; 1990; 5 Suppl 1():141-8. PubMed ID: 2182057
[TBL] [Abstract][Full Text] [Related]
35. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective.
Wright C; Schnoll S; Bernstein D
Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964
[TBL] [Abstract][Full Text] [Related]
36. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
[TBL] [Abstract][Full Text] [Related]
37. Post-approval evaluation of effectiveness of risk minimisation: methods, challenges and interpretation.
Banerjee AK; Zomerdijk IM; Wooder S; Ingate S; Mayall SJ
Drug Saf; 2014 Jan; 37(1):33-42. PubMed ID: 24357107
[TBL] [Abstract][Full Text] [Related]
38. Risk management from an Asian/Pacific Rim regulatory perspective.
McEwen J
Drug Saf; 2004; 27(8):491-7. PubMed ID: 15154822
[TBL] [Abstract][Full Text] [Related]
39. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
40. Minimizing risks to drugs.
Kshirsagar NA; Gogtay NJ
J Assoc Physicians India; 2008 Jul; 56():556-7. PubMed ID: 18846914
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
